Preparation and biological evaluation of 99mTc-HYNIC-H1299.2 peptide for targeting and imaging of ovarian cancer
محل انتشار: بیست و دومین همایش سالیانه پزشکی هسته ای ایران
سال انتشار: 1397
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 443
نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
این مقاله در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
RINMMICMED22_042
تاریخ نمایه سازی: 30 آذر 1398
چکیده مقاله:
Background: Targeted molecular imaging techniques have become indispensable tools in modern diagnostics because they provide accurate and specific diagnosis of disease information. Peptides are known a class of targeting agents that could be used as molecular imaging tools.Methods: In this study, the modified peptide Ac-H1299.2 (YAAWPASGAWTGTAP) was selected and conjugated with HYNIC via lysine amino acid on C-terminus and labeled with 99mTc using tricine and EDDA as the co-ligands. These radiotracers were evaluated for potential use in diagnostic imaging of ovarian cancer cells (SKOV-3). The cell-specificity of these radiolabeled peptides was determined by their binding on an ovarian cancer cell line (SKOV-3) also displayed low affinity for lung adenocarcinoma cell line (A549) and breast cancer cell line (MCF7). Biodistributions were showed in normal and nude mice bearing SKOV-3 ovarian cell line. Finally, we demonstrated the tumor targeting in (SKOV-3) xenografted nude mice by SPECT imaging.Results: Both 99mTc-labeled peptides were labeled with 99mTc with more than 98% efficiency and were showed high stability in buffer and serum. We observed nanomolar binding affinities for both radiolabeled peptides. The tumor uptakes were 3.27 ± 0.48% and 1.55 ± 0.24% for tricine and 2.34 ± 1.11% and 1.09 ± 0.18% for EDDA/ tricine at 1 and 4 h after injection, respectively. However, tumor uptakes were similar for both peptides at 1 h postinjection, a higher tumor to background ratio and lower radioactivity in the blood were observed for EDDA/ tricine co-ligands, leading to clear tumor visualization in imaging with injection of this peptide.Conclusion: This new radiopeptide was selectively targeted for ovarian cancer, and introduction of a (EDDA/ tricine) as co-ligand improved the pharmacokinetics of 99mTc labeled H1299.2 for tumor imaging in animals.
کلیدواژه ها:
نویسندگان
Seyedeh Atekeh Torabizadeh
Pharmaceutics Research Centre, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
Seyed Jalal Hosseinimhr
Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran